Ziarco nets $33.1 mln Series B

Ziarco has closed $33.1 million in Series B funding.New Enterprise Associates and Lundbeckfond Ventures led the round. In addition to the funding, Ed Mathers, a partner at NEA, has been appointed chairman of Ziarco’s board of directors. Also, Johan Kördel, a senior partner at Lundbeckfond Ventures, has been added to the board. Ziarco is a biopharmaceutical firm focused on inflammatory skin diseases.

Canterbury, UK, Monday 10th November, 2014 — Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B financing round. New Enterprise Associates, Inc. (NEA) and Lundbeckfond Ventures co-led the round with new investor Amgen Ventures joining the existing investors BVF Partners L.P. and Pfizer Venture Investments. Ed Mathers, partner at NEA, has joined Ziarco’s board of directors as Chairman. Johan Kördel, senior partner at Lundbeckfond Ventures, has also joined the board.

Ziarco plans to use the proceeds from the Series B financing to generate clinical Proof-of-Concept data in patients for its lead compounds – ZPL-389, an oral histamine H4 receptor antagonist, and ZPL-521, a topical cytosolic phospholipase A2 (cPLA2) inhibitor, in atopic dermatitis and psoriasis, respectively.

“We are pleased to have completed this Series B financing and view the participation of new and existing investors as validation of our high-quality clinical programs in underserved dermatological diseases, as well as our seasoned management team,” said Mike Yeadon, Ph.D., President and Chief Executive Officer of Ziarco. “The proceeds will enable us to generate clinical Proof-of-Concept for both of our lead compounds and make progress in addressing the substantial unmet medical needs and dissatisfaction with the current care options for patients living with atopic dermatitis and psoriasis. We look forward to advancing ZPL-389 into a Phase 2a study for atopic dermatitis, as well as to initiating a patient study of the topical formulation of ZPL-521 for psoriasis.”